Compare Tango Therapeutics Inc. (TNGX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Wynn Resorts, Limited — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Wynn Resorts, Limited trades at $73.21 (market cap $7.79B). The key difference: Wynn Resorts, Limited is far larger — about 2.1× Tango Therapeutics Inc.'s market cap, and Wynn Resorts, Limited pays a 1.32% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Wynn Resorts, Limited for 77 Days on average.
| TNGX | WYNN | |
|---|---|---|
Market Cap | $3.75B | $7.79B |
Volume | 9,619,106 | 1,551,566 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $133.09 |
52-Week Low | $7.50 | $73.73 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.77B | $18.04B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Wynn Resorts (WYNN) trades at $73.73, down 1.64% on the day, amid a bearish technical signal. The stock shows strong analyst support with a 64% buy rating and a consensus price target of $130.73, implying significant upside. Recent Q2 2026 earnings beat expectations, driven by Macau strength, though U.S. margins face pressure. The company maintains solid revenue growth, with 2026 revenue projected at $7.4B, but net cash flow remains negative due to high capital expenditures for expansion projects like Wynn Al Marjan.
The outlook for WYNN is cautiously optimistic, with Macau recovery and new project potential offering growth opportunities. However, risks include elevated debt levels, rising capex, and competitive pressures. Investors should weigh the substantial upside projected by analysts against execution risks and macroeconomic sensitivities affecting the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
